OTC: IDRSF - Idorsia Ltd

Доходность за полгода: -5.58%
Сектор: Healthcare

График акции Idorsia Ltd


О компании

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

Подробнее
Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Основные параметры

Цена ао 2.64
Выручка 0.0231
EBITDA -0.4478
Число акций ао 0.17743 млрд
P/S 33.54
P/BV 3.09
EV/EBITDA -9.62
Сайт https://www.idorsia.com
Изменение цены за день: 0% (2.03)
Изменение цены за неделю: -25.91% (2.74)
Изменение цены за месяц: +6.84% (1.9)
Изменение цены за 3 месяца: +1.4493% (2.001)
Изменение цены за полгода: -5.58% (2.15)
Изменение цены за год: -80.99% (10.68)
Изменение цены с начала года: -7.73% (2.2)


Все параметры ⇨

Оценка

Недооценка

Название Значение Оценка
P/S 33.54 1
P/BV 3.09 0
P/E 0 0
EV/EBITDA -9.62 0
Итого:

Эффективность

Название Значение Оценка
ROA, % -73.36 0
ROE, % 292.59 10
Итого:

Дивиденды

Название Значение Оценка
Div yield, % 0 0
DSI 0 0
Итого:

Долг

Название Значение Оценка
Debt/EBITDA -1.5719 10
Итого:

Импульс роста

Название Значение Оценка
Рост прибыли, % 12.97 3
Рост цены акции, % 0 0
Рост дивидендов, % 0 0
Итого:

Основные владельцы

Институционалы Объем Доля, %
Fidelity Select Portfolios - Biotechnology 4866770 2.58
Smallcap World Fund 2270994 1.2
Vanguard International Stock Index-Total Intl Stock Indx 1627551 0.86
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 958060 0.51
iShares Core MSCI EAFE ETF 628695 0.33
Fidelity Growth Company Fund 623409 0.33
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 479318 0.25
iShares MSCI EAFE Small Cap ETF 426739 0.23
Vanguard International Stock Index-Vanguard European Stock Index 252174 0.13
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 238962 0.13

Похожие компании



Руководство компании

Руководитель Должность Оплата Год рождения
Mr. Jean-Paul Clozel M.D. CEO & Executive Director 1.53M 1955 (69 лет)
Mr. André C. Muller Executive VP & CFO N/A 1963 (61 год)
Dr. Martine Clozel Executive VP & Chief Scientific Officer N/A 1955 (69 лет)
Mr. Andrew C. Weiss Senior VP and Head of Investor Relations & Corporate Communications N/A 1968 (56 лет)
Mr. Julien Gander L.L.M. Senior VP, Group General Counsel & Company Secretary N/A 1979 (45 лет)
Mr. Alexander Khatuntsev Senior VP & Head of Global Human Resources N/A 1978 (46 лет)
Dr. Guy Braunstein M.D. Executive VP & Chief Medical Officer N/A 1956 (68 лет)
Mr. Olivier Lambert Senior VP & Head of Technical Operations N/A 1966 (58 лет)
Mr. Markus A. Riederer Senior VP & Head of Drug Discovery Biology N/A 1962 (62 года)
Mr. Christoph Boss Senior VP & Head of Drug Discovery Chemistry N/A 1968 (56 лет)

Информация о компании

Адрес: Switzerland, Allschwil, Hegenheimermattweg 91 - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.idorsia.com
Телефон: +tel:41588441010